These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

262 related items for PubMed ID: 15703820

  • 1. Heregulin-triggered Her-2/neu signaling enhances nuclear accumulation of p21WAF1/CIP1 and protects breast cancer cells from cisplatin-induced genotoxic damage.
    Menendez JA, Mehmi I, Lupu R.
    Int J Oncol; 2005 Mar; 26(3):649-59. PubMed ID: 15703820
    [Abstract] [Full Text] [Related]

  • 2. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.
    Menendez JA, Mehmi I, Atlas E, Colomer R, Lupu R.
    Int J Oncol; 2004 Mar; 24(3):591-608. PubMed ID: 14767544
    [Abstract] [Full Text] [Related]

  • 3. Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene.
    Pietras RJ, Poen JC, Gallardo D, Wongvipat PN, Lee HJ, Slamon DJ.
    Cancer Res; 1999 Mar 15; 59(6):1347-55. PubMed ID: 10096569
    [Abstract] [Full Text] [Related]

  • 4. Heregulin beta1 promotes breast cancer cell proliferation through Rac/ERK-dependent induction of cyclin D1 and p21Cip1.
    Yang C, Klein EA, Assoian RK, Kazanietz MG.
    Biochem J; 2008 Feb 15; 410(1):167-75. PubMed ID: 17941827
    [Abstract] [Full Text] [Related]

  • 5. Blocking HER-2/HER-3 function with a dominant negative form of HER-3 in cells stimulated by heregulin and in breast cancer cells with HER-2 gene amplification.
    Ram TG, Schelling ME, Hosick HL.
    Cell Growth Differ; 2000 Mar 15; 11(3):173-83. PubMed ID: 10768865
    [Abstract] [Full Text] [Related]

  • 6. Tea polyphenol (-)-epigallocatechin 3-gallate suppresses heregulin-beta1-induced fatty acid synthase expression in human breast cancer cells by inhibiting phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase cascade signaling.
    Pan MH, Lin CC, Lin JK, Chen WJ.
    J Agric Food Chem; 2007 Jun 27; 55(13):5030-7. PubMed ID: 17539658
    [Abstract] [Full Text] [Related]

  • 7. Overexpression and hyperactivity of breast cancer-associated fatty acid synthase (oncogenic antigen-519) is insensitive to normal arachidonic fatty acid-induced suppression in lipogenic tissues but it is selectively inhibited by tumoricidal alpha-linolenic and gamma-linolenic fatty acids: a novel mechanism by which dietary fat can alter mammary tumorigenesis.
    Menendez JA, Ropero S, Mehmi I, Atlas E, Colomer R, Lupu R.
    Int J Oncol; 2004 Jun 27; 24(6):1369-83. PubMed ID: 15138577
    [Abstract] [Full Text] [Related]

  • 8. Trastuzumab in combination with heregulin-activated Her-2 (erbB-2) triggers a receptor-enhanced chemosensitivity effect in the absence of Her-2 overexpression.
    Menendez JA, Mehmi I, Lupu R.
    J Clin Oncol; 2006 Aug 10; 24(23):3735-46. PubMed ID: 16847284
    [Abstract] [Full Text] [Related]

  • 9. Herstatin inhibits heregulin-mediated breast cancer cell growth and overcomes tamoxifen resistance in breast cancer cells that overexpress HER-2.
    Jhabvala-Romero F, Evans A, Guo S, Denton M, Clinton GM.
    Oncogene; 2003 Nov 06; 22(50):8178-86. PubMed ID: 14603258
    [Abstract] [Full Text] [Related]

  • 10. Heregulin beta1-activated phosphatidylinositol 3-kinase enhances aggregation of MCF-7 breast cancer cells independent of extracellular signal-regulated kinase.
    Tan M, Grijalva R, Yu D.
    Cancer Res; 1999 Apr 01; 59(7):1620-5. PubMed ID: 10197638
    [Abstract] [Full Text] [Related]

  • 11. Heregulin-beta is especially potent in activating phosphatidylinositol 3-kinase in nontransformed human mammary epithelial cells.
    Ram TG, Hosick HL, Ethier SP.
    J Cell Physiol; 2000 Jun 01; 183(3):301-13. PubMed ID: 10797304
    [Abstract] [Full Text] [Related]

  • 12. A deletion mutant of heregulin increases the sensitivity of breast cancer cells to chemotherapy without promoting tumorigenicity.
    Atlas E, Bojanowski K, Mehmi I, Lupu R.
    Oncogene; 2003 May 29; 22(22):3441-51. PubMed ID: 12776196
    [Abstract] [Full Text] [Related]

  • 13. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs.
    Pietras RJ, Pegram MD, Finn RS, Maneval DA, Slamon DJ.
    Oncogene; 1998 Oct 29; 17(17):2235-49. PubMed ID: 9811454
    [Abstract] [Full Text] [Related]

  • 14. Overexpression of basic fibroblast growth factor in MCF-7 human breast cancer cells: lack of correlation between inhibition of cell growth and MAP kinase activation.
    Wieder R, Fenig E, Wang H, Wang Q, Paglin S, Menzel T, Gabrilove J, Fuks Z, Yahalom J.
    J Cell Physiol; 1998 Dec 29; 177(3):411-25. PubMed ID: 9808150
    [Abstract] [Full Text] [Related]

  • 15. A bidirectional "alpha(v)beta(3) integrin-ERK1/ERK2 MAPK" connection regulates the proliferation of breast cancer cells.
    Vellon L, Menendez JA, Lupu R.
    Mol Carcinog; 2006 Oct 29; 45(10):795-804. PubMed ID: 16705745
    [Abstract] [Full Text] [Related]

  • 16. Transcriptional up-regulation of paxillin expression by heregulin in human breast cancer cells.
    Vadlamudi R, Adam L, Tseng B, Costa L, Kumar R.
    Cancer Res; 1999 Jun 15; 59(12):2843-6. PubMed ID: 10383144
    [Abstract] [Full Text] [Related]

  • 17. HER-2/neu transcriptionally activates Jab1 expression via the AKT/beta-catenin pathway in breast cancer cells.
    Hsu MC, Chang HC, Hung WC.
    Endocr Relat Cancer; 2007 Sep 15; 14(3):655-67. PubMed ID: 17914096
    [Abstract] [Full Text] [Related]

  • 18. Why does tumor-associated fatty acid synthase (oncogenic antigen-519) ignore dietary fatty acids?
    Menendez JA, Colomer R, Lupu R.
    Med Hypotheses; 2005 Sep 15; 64(2):342-9. PubMed ID: 15607569
    [Abstract] [Full Text] [Related]

  • 19. EGF receptor and p21WAF1 expression are reciprocally altered as ME-180 cervical carcinoma cells progress from high to low cisplatin sensitivity.
    Donato NJ, Perez M, Kang H, Siddik ZH, Ling YH, Perez-Soler R.
    Clin Cancer Res; 2000 Jan 15; 6(1):193-202. PubMed ID: 10656450
    [Abstract] [Full Text] [Related]

  • 20. Mitogenic activity of neu differentiation factor/heregulin mimics that of epidermal growth factor and insulin-like growth factor-I in human mammary epithelial cells.
    Ram TG, Kokeny KE, Dilts CA, Ethier SP.
    J Cell Physiol; 1995 Jun 15; 163(3):589-96. PubMed ID: 7775601
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.